Clinical Trial Update: A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine [Phase 1]

View source ↗

Summary

Phase I dose-escalation study of oral SB939 alone or with azacitidine has completed, assessing safety/dosing in solid tumors and hematologic malignancies includ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Myelodysplastic Syndromes
• Solid Tumors

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• SB939 (SB-939)

Snippet

Sponsor: S*BIO | Conditions: Solid Tumors, Hematologic Malignancies | Phase 1 | Status: COMPLETED